Dr. Tareq Abadl: Low-Titer Group O Whole Blood – Faster, Simpler Resuscitation for Severe Hemorrhage
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Low-Titer Group O Whole Blood (LTOWB)
Faster, simpler resuscitation for severe hemorrhage
What it is
Whole blood from low-titer group O donors, containing RBCs + plasma + platelets in a single unit. Can be issued immediately when patient blood type is unknown—critical in massive bleeding.
Why it matters in trauma care?
- Speed: One product, rapid release → shorter time to first transfusion
- Physiology: Delivers balanced hemostatic resuscitation from the start
Evidence: Observational studies and cohort analyses link earlier LTOWB with lower early mortality and faster resuscitation vs component therapy
- Operational advantages
- Simplified logistics: Replace multiple components with one unit
- Prehospital-ready: Suits EMS, aeromedical, and austere settings
- Inventory efficiency: Streamlined storage and deployment pathways
Safety and evidence status
Reassuring safety signals in civilian use so far
Ongoing RCTs clarifying superiority vs equivalence to components
- Key policy decisions:
Anti-A/B titer thresholds
Leukoreduction strategy
Hemovigilance and outcome tracking
Supply balance to avoid shortages
- Practical implementation notes
- Define indications: Major hemorrhage, prehospital trauma, MTP entry
- Specify product: Titer limits, leukoreduction (if used), storage conditions
- Train teams: Ordering, handling, documentation (ED, OR, EMS)
- Coordinate early: Transfusion committee + regional blood services
Bottom line
LTOWB is a pragmatic, evidence-informed tool that shortens time to transfusion and simplifies hemorrhage resuscitation. It complements—not replaces—component therapy. Adoption should be guided by local epidemiology, supply logistics, and formal policy.
Read more from Dr. Tareq Abadl on Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia